Versameb is a Swiss based biotechnology platform company focusing on the optimized local delivery of therapeutic proteins, currently focusing on applications in regenerative medicine. Our vision is to both improve existing therapies as well as develop transformative therapies in entirely new applications in disease indications of high medial need. Versameb is funded by private international investors. We are committed to create substantial long-term value for our patients, shareholders and other stakeholders.

ir@versameb.com | versameb.com/